| |
| |
|
| Insider
Information: |
Weiss Michael S |
| Relationship: |
Director |
| City: |
Berkeley Heights |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
16,329,233 |
|
|
Indirect Shares
|
14,546,388 |
|
|
| Direct
Value |
$207,679,882 |
|
|
|
Indirect Value
|
$228,994,301 |
|
|
| Total
Shares |
30,875,621 |
|
|
| Total
Value |
$436,674,183 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -2.8%
|
-135.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
10% Owner |
2010-05-10 |
1,320,418 |
2003-11-21 |
0 |
Premium* |
|
|
Genta Inc De |
GNTAQ |
Director |
2005-08-05 |
537,238 |
2004-07-14 |
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
Director |
2008-08-22 |
25,000 |
|
0 |
Premium* |
|
|
TG Therapeutics Inc |
TGTX |
CEO |
2024-01-06 |
13,074,929 |
2020-06-22 |
14,434,214 |
Premium* |
|
|
Fortress Biotech, Inc. |
FBIO |
See Remarks, Director,... |
2024-01-01 |
1,346,985 |
2013-12-19 |
0 |
Premium* |
|
|
Checkpoint Therapeutics, Inc. |
CKPT |
Director |
2017-06-15 |
0 |
2024-05-14 |
112,174 |
Premium* |
|
|
Avenue Therapeutics, Inc. |
ATXI |
Director |
2018-08-07 |
24,663 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2020-06-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,556,029 |
14,434,214 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
See Remarks |
• • • |
2021-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,030,339 |
11,232,150 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2021-06-10 |
4 |
A |
$0.00 |
$0 |
I/I |
16,502 |
78,782 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2021-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,080,770 |
14,148,852 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2021-12-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
14,145,852 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2021-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
709,000 |
13,436,852 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2021-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
56,394 |
13,493,246 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
See Remarks |
• • • |
2022-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,102,986 |
12,335,136 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
I/I |
47,619 |
126,401 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
See Remarks |
• • • |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,219,294 |
13,554,430 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO and President |
• • – |
2023-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
985,000 |
11,973,021 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
17,483 |
30,123 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
See Remarks |
• • • |
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
216,465 |
1,346,985 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
CEO |
• • – |
2024-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,001,908 |
13,074,929 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2024-05-14 |
4 |
A |
$0.00 |
$0 |
I/I |
82,051 |
112,174 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2008-08-22 |
4 |
B |
$0.40 |
$40,000 |
D/D |
100,000 |
115,000 |
2.81 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2008-08-26 |
4 |
B |
$0.41 |
$20,500 |
D/D |
50,000 |
165,000 |
2.81 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
See Remarks |
• • • |
2023-02-10 |
4 |
B |
$0.84 |
$999,999 |
D/D |
1,197,604 |
14,752,034 |
3.23 |
% |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-02-21 |
4 |
OE |
$1.30 |
$52,000 |
D/D |
40,000 |
55,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-03-21 |
4 |
OE |
$1.30 |
$104,000 |
D/D |
80,000 |
95,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chariman and CEO |
• • – |
2006-04-18 |
4 |
OE |
$1.30 |
$52,000 |
D/D |
40,000 |
55,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-05-16 |
4 |
OE |
$1.30 |
$52,000 |
D/D |
40,000 |
55,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-06-20 |
4 |
OE |
$1.30 |
$52,000 |
D/D |
40,000 |
55,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-07-18 |
4 |
OE |
$1.30 |
$13,000 |
D/D |
10,000 |
25,000 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chairman and CEO |
• • – |
2006-12-07 |
4 |
OE |
$1.30 |
$69,466 |
D/D |
53,435 |
68,435 |
0 |
- |
|
126 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
